Phase II study of oral etoposide for patients with advanced breast cancer

Background. The objective of this study was to define the activity and toxicity of etoposide for patients with previously treated metastatic breast cancer.

[1]  D. V. Van Echo,et al.  Doxorubicin plus VP-16-213 for the treatment of refractory breast carcinoma. , 1982, American journal of clinical oncology.

[2]  M. Ratain,et al.  New perspectives on the toxicity of etoposide. , 1992, Seminars in oncology.

[3]  E. Smit,et al.  A phase II study of oral etoposide in elderly patients with small cell lung cancer. , 1989, Thorax.

[4]  D. Henry,et al.  Changing patterns of care in the management of anemia. , 1992, Seminars in oncology.

[5]  J. Hainsworth,et al.  Chronic daily administration of oral etoposide--a phase I trial. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[6]  C. Vaughn,et al.  VP-16 and adriamycin in patients with advanced breast cancer. , 1982, American journal of clinical oncology.

[7]  M. Slevin,et al.  Low-dose oral etoposide: a new role for an old drug? , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  C. Boni,et al.  Cisplatin and etoposide as first-line chemotherapy for metastatic breast carcinoma: a prospective randomized trial of the Italian Oncology Group for Clinical Research. , 1991, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[9]  W. Evans,et al.  Changes in the clearance of total and unbound etoposide in patients with liver dysfunction. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  F. Behm,et al.  Secondary acute myeloid leukemia in children treated for acute lymphoid leukemia. , 1989, The New England journal of medicine.

[11]  L. Einhorn,et al.  Phase II trial of daily oral VP-16 in refractory small cell lung cancer: a Hoosier Oncology Group study. , 1990, Seminars in oncology.

[12]  Rosa R. Silva,et al.  Etoposide and Mitomycin-C in Pretreated Metastatic Breast Cancer , 1989, Tumori.

[13]  R. Motzer,et al.  Acute nonlymphocytic leukemia in germ cell tumor patients treated with etoposide-containing chemotherapy. , 1993, Journal of the National Cancer Institute.

[14]  L. Einhorn,et al.  Phase II study of daily oral etoposide in refractory germ cell tumors. , 1990, Seminars in oncology.

[15]  J. Hainsworth,et al.  Prolonged administration of oral etoposide in patients with relapsed or refractory small-cell lung cancer: a phase II trial. , 1990, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  R. Benjamin,et al.  Standard and high dose chemotherapy for advanced soft tissue sarcomas. , 1992, Annals of oncology : official journal of the European Society for Medical Oncology.

[17]  G. Sledge,et al.  Progress in chemotherapy for metastatic breast cancer. , 1992, Seminars in oncology.

[18]  J. Ingle,et al.  An evaluation of two schedules of VP-16 and adriamycin in patients with advanced breast cancer. , 1980, Oncology.

[19]  S. Green,et al.  VP-16 + adriamycin vs. adriamycin alone in advanced adenocarcinoma of the breast, phase II, a randomized trial: a Southwest Oncology Group Study. , 1988, Medical and pediatric oncology.

[20]  L. Einhorn,et al.  Secondary leukemia associated with a conventional dose of etoposide: review of serial germ cell tumor protocols. , 1993, Journal of the National Cancer Institute.

[21]  C. Hudis,et al.  Phase II trial of carboplatin and etoposide in metastatic breast cancer , 1993, Cancer.

[22]  Craig R. Nichols.  Role of etoposide in treatment of breast cancer. , 1992, Seminars in oncology.

[23]  C. Charlton,et al.  Long-term oral etoposide in metastatic breast cancer: clinical and pharmacokinetic results. , 1993, Cancer treatment reviews.

[24]  J. Garcia-conde,et al.  Clinical activity of chronic oral etoposide in previously treated metastatic breast cancer. , 1994, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  R Simon,et al.  Designs for efficient clinical trials. , 1989, Oncology.

[26]  D G Lowe,et al.  A randomized trial to evaluate the effect of schedule on the activity of etoposide in small-cell lung cancer. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.